• The Precision Peptide Company signed a compounding agreement with a U.S.-based 503A sterile compounding pharmacy for prescription peptide fulfillment.
• Work is expected to start June 1, 2026, with capacity of up to 25,000 prescriptions per day across all U.S. states.
• Products under the deal will be 100% compounded in the United States, including BPC-157.
• The partner’s identity was not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Precision Peptide Company Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202606020700NEWSFILECNPR____20260602_299757_1) on June 02, 2026, and is solely responsible for the information contained therein.